Biotech Stock Report 10.03.09
Tuesday, 10 March, 2009
The pharmaceuticals and biotechnology sector was mostly flat recording a small 0.11% increase for the day.
Market heavyweight CSL (ASX:CSL) was stable, up 28c to $35.44.
Living Cell Technologies (ASX:LCT) recorded spectacular increase of 31%, to close at 10.5c but is still trading near its 52 week low of 8c.
Prana Biotechnology (ASX:PBT) and IDT Australia (ASX:IDT) were among the day's weaker performers in the pharmaceuticals and biotechnology sector, down 8% and 6% respectively with Bionomics Limited (ASX:BNO) not far behind, 5% down to 20c.
Chemgenex Pharmaceuticals (ASX:CXS) recorded a solid 6% rise to 34c, but is still well down on its 52 week high of $1.25. Novogen and Progen also moved up over 3%.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
